3 results about "Jatrorrhizine" patented technology

The application belongs to the technical field of biological medicine, and specifically discloses application of jatrorrhizine in preparation of a medicine for preventing and treating intestinal radiation injury, and a medicine for preventing and treating intestinal radiation injury.The application verifies the effect of jatrorrhizine on resisting intestinal radiation injury by using an intestinal organ model, wherein the jatrorrhizine can obviously improve the changes in survival rate, bud number and organ size of the intestinal organ caused by radiation injury, and eliminate the adverse effects caused by the intestinal radiation injury.After abdominal irradiation injury of experimental mice, jatrorrhizine is injected into the abdominal cavity, the intestinal length is obviously increased, the survival rate is improved, and HE staining of small intestinal sections shows that the crypt depth and villus structure are improved.It is proved that the jatrorrhizine can promote the regeneration and repair of the intestinal organ after radiation, improve the survival rate, and improve the morphological changes of the intestinal caused by radiation injury.The medicine containing the jatrorrhizine provided by the application can improve the intestinal lesions caused by radiation injury, relieve the intestinal injury symptoms, and improve the survival rate of individuals.

The invention discloses preparation and application of a novel magnolol and jatrorrhizine conjugate, relates to the technical field of medicines, and aims to overcome the defects of poor drug resistance and insufficient activity of a single-target anti-cancer drug. According to the technical scheme, acetone or acetonitrile is used as a solvent, and through a two-step substitution reaction, the magnolol and jatrorrhizine conjugate is obtained; the preparation method comprises the following steps: reacting magnolol with dibromo-alkane to generate an intermediate B, and conjugating the intermediate B with jatrorrhizine to obtain a final product with a general formula C; or the jatrorrhizine reacts with dibromo alkane to generate an intermediate E, and then the intermediate E is conjugated with magnolol to obtain the final product of the general formula C. In the preparation process, reaction conditions (such as potassium carbonate alkaline environment and 82 DEG C reflux) are optimized, and high yield and purity are realized. The conjugate disclosed by the invention is widely applied to the anti-tumor field, has remarkable inhibitory activity on various cancer cells (such as non-small cell lung cancer cells HCC827 and human lung adenocarcinoma cells H1975), has better effects than magnolol and jateorhizine monomers, and provides a new candidate for research and development of multi-target drugs.

The application discloses a method for simultaneously determining the contents of 12 components in Longqing capsules by HPLC. The method comprises simultaneously determining the contents of paeoniflorin, paeonol, chlorogenic acid, caffeic acid, berberine hydrochloride, coptisine, jatrorrhizine hydrochloride, gallic acid, rutin, kaempferol, luteolin and phellodendrine hydrochloride in the Longqing capsules, gradient elution is carried out by adopting a chromatographic column with octadecylsilane-bonded silica gel as a filler, 0.1% phosphoric acid as mobile phase A and a methanol solution as mobile phase B, the column temperature is 35 DEG C, and the detection wavelength is 270 nm, and the HPLC content determination method is established, so that a multi-index quality control method of the Longqing capsules is established. The method is simple, stable and reliable, has high detection efficiency, and has reference value for establishing the quality standard and control system of the Longqing capsules based on the theory of traditional Chinese medicine.